Chemoinformaics analysis of (1S,3R,5S)-4-METHYLIDENE-1-PROPAN-2-YLBICYCLO[3.1.0]HEXAN-3-OL
| Molecular Weight | 152.237 | nRot | 1 |
| Heavy Atom Molecular Weight | 136.109 | nRig | 20 |
| Exact Molecular Weight | 152.12 | nRing | 2 |
| Solubility: LogS | -2.221 | nHRing | 0 |
| Solubility: LogP | 0.253 | No. of Aliphatic Rings | 2 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 2 |
| Atoms Count | 27 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 11 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 2 |
| No. of Hydrogen atom | 16 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 10 | No. of Saturated Rings | 2 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 28.1707 |
| nHD | 1 | BPOL | 16.0513 |
| QED | 0.312 |
| Synth | 6.421 |
| Natural Product Likeliness | 3.134 |
| NR-PPAR-gamma | 0.012 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.008 |
| Pgp-sub | 0.739 |
| HIA | 0.955 |
| CACO-2 | -5.297 |
| MDCK | 0.000241306 |
| BBB | 0.462 |
| PPB | 0.281111 |
| VDSS | 0.639 |
| FU | 0.426304 |
| CYP1A2-inh | 0.002 |
| CYP1A2-sub | 0.102 |
| CYP2c19-inh | 0.002 |
| CYP2c19-sub | 0.51 |
| CYP2c9-inh | 0.003 |
| CYP2c9-sub | 0.246 |
| CYP2d6-inh | 0.004 |
| CYP2d6-sub | 0.134 |
| CYP3a4-inh | 0.055 |
| CYP3a4-sub | 0.068 |
| CL | 1.73 |
| T12 | 0.102 |
| hERG | 0.019 |
| Ames | 0.049 |
| ROA | 0.825 |
| SkinSen | 0.016 |
| Carcinogencity | 0.01 |
| EI | 0.007 |
| Respiratory | 0.15 |
| NR-Aromatase | 0.102 |
| Antiviral | No |
| Prediction | 0.940574 |